Fundz

Acelrx Pharmaceuticals announced it raised $4.92 Million in an initial filing from an offering of $15 Million

PUBLIC · TLPHApr 17, 2025

Amount Raised

$4.92 Million

Round Type

Seed

HaywardManufacturingBiotechnologyHealthcareHealth CarePharmaceutical

Company Information

Company

ACELRX PHARMACEUTICALS

Location

25821 INDUSTRIAL BOULEVARD

Hayward, California, United States

About

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. AcelRx’s lead product candidate, Niyad is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption, or IDE, as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation Status from the FDA. AcelRx is also developing two pre-filled syringes in-licensed from its partner Aguettant: Fedsyra™, a pre-filled ephedrine syringe, with an expected NDA filing in the first half of 2023, and PFS-02, a pre-filled phenylephrine syringe with an expected NDA filing in 2024.

Fundz sees it the moment ACELRX PHARMACEUTICALS raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsHoward R., Director hidden hidden hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for ACELRX PHARMACEUTICALS's next move

See what Strategic adds

ACELRX PHARMACEUTICALS raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.